[go: up one dir, main page]

WO2009158007A3 - Methods and compositions for therapeutic treatment - Google Patents

Methods and compositions for therapeutic treatment Download PDF

Info

Publication number
WO2009158007A3
WO2009158007A3 PCT/US2009/003798 US2009003798W WO2009158007A3 WO 2009158007 A3 WO2009158007 A3 WO 2009158007A3 US 2009003798 W US2009003798 W US 2009003798W WO 2009158007 A3 WO2009158007 A3 WO 2009158007A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
efflux
increase
therapeutic treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/003798
Other languages
French (fr)
Other versions
WO2009158007A2 (en
Inventor
Wendye Robbins
Ving Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Limerick Biopharma Inc
Original Assignee
Limerick Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Limerick Biopharma Inc filed Critical Limerick Biopharma Inc
Publication of WO2009158007A2 publication Critical patent/WO2009158007A2/en
Publication of WO2009158007A3 publication Critical patent/WO2009158007A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Methods and compositions are described for the modulation of effects of therapeutic agents. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of therapeutic agents out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide for the increase of efflux transporter activity at blood-tissue, and blood- CSF barriers to increase the efflux of therapeutic agent from physiological compartments, including central nervous system.
PCT/US2009/003798 2008-06-27 2009-06-26 Methods and compositions for therapeutic treatment Ceased WO2009158007A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7659108P 2008-06-27 2008-06-27
US7657808P 2008-06-27 2008-06-27
US61/076,591 2008-06-27
US61/076,578 2008-06-27

Publications (2)

Publication Number Publication Date
WO2009158007A2 WO2009158007A2 (en) 2009-12-30
WO2009158007A3 true WO2009158007A3 (en) 2010-04-01

Family

ID=41445145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/003798 Ceased WO2009158007A2 (en) 2008-06-27 2009-06-26 Methods and compositions for therapeutic treatment

Country Status (1)

Country Link
WO (1) WO2009158007A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2182957A4 (en) * 2007-07-31 2012-07-18 Limerick Biopharma Inc Phosphorylated pyrone analogs and methods
EP2355814A2 (en) * 2008-10-10 2011-08-17 Limerick BioPharma, Inc. Pyrones for the treatment of metabolic disorders
EP2709704B1 (en) * 2011-05-17 2016-11-30 Joanneum Research Forschungsgesellschaft mbH Catheter having a healing dummy
CN102973551A (en) * 2011-09-07 2013-03-20 温州医学院 Use of fisetin for preparing medicaments for treatment of depression.
WO2014185601A1 (en) * 2013-05-16 2014-11-20 (주)생명의나무 Pharmaceutical composition for preventing or treating menopausal symptoms containing flavonoid compound derived from toxicodendron vernicifluum extract as active ingredient
KR101809379B1 (en) * 2016-10-13 2017-12-14 연세대학교 산학협력단 Composition comprising Diosmin or as active ingredients for Preventing or treating muscle disease
KR101956667B1 (en) * 2017-06-08 2019-06-19 한국과학기술연구원 Composition for inducing male hormone production
CN114948929A (en) * 2022-04-08 2022-08-30 上海市中医医院 A kind of use of quercetin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006025431A1 (en) * 2004-08-31 2006-03-09 Japanese Foundation For Cancer Research Antagonist against tolerance to anticancer drugs
US20060111308A1 (en) * 2004-11-16 2006-05-25 Wendye Robbins Methods and compositions for therapeutic treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006025431A1 (en) * 2004-08-31 2006-03-09 Japanese Foundation For Cancer Research Antagonist against tolerance to anticancer drugs
US20060111308A1 (en) * 2004-11-16 2006-05-25 Wendye Robbins Methods and compositions for therapeutic treatment

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DAGENAIS C ET AL.: "Variable modulation of opioid brain uptake by P- glycoprotein in mice.", BIOCHEM. PHARMACOL., vol. 67, no. 2, 15 January 2004 (2004-01-15), pages 269 - 276 *
DANIELL HW.: "Hypogonadism in men consuming sustained-action oral opioids.", J. PAIN., vol. 3, no. 5, October 2002 (2002-10-01), pages 377 - 384 *
LETRENT SP ET AL.: "Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat.", DRUG METAB DISPOS., vol. 27, no. 7, July 1999 (1999-07-01), pages 827 - 834 *
RODRIGUEZ M ET AL.: "Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat.", J. PHARM. PHARMACOL., vol. 56, no. 3, March 2004 (2004-03-01), pages 367 - 374 *
WANG YH ET AL.: "An in silico approach for screening flavonoids as P- glycoprotein inhibitors based on a Bayesian-regularized neural network.", J. COMPUT. AIDED MOL. DES., vol. 19, no. 3, March 2005 (2005-03-01), pages 137 - 147 *

Also Published As

Publication number Publication date
WO2009158007A2 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
WO2008083160A3 (en) Methods and compositions for therapeutic treatment
WO2006055672A3 (en) Methods and compositions for treating pain
WO2009158007A3 (en) Methods and compositions for therapeutic treatment
WO2008070346A3 (en) Methods for treating pain with reduced nuasea and vomiting
WO2009158031A3 (en) Methods and compositions for therapeutic treatment
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2012062925A3 (en) Compounds and methods for treating pain
WO2009129246A3 (en) Compositions and methods for preparing and using same
IL245290A0 (en) Transdermal therapeutic system for administering the active substance buprenorphine
EP2024018A4 (en) Portable assemblies, systems, and methods for providing functional or therapeutic neurostimulation
MX2014003180A (en) Methods for treating hcv.
WO2012054862A9 (en) Agents, compositions, and methods for treating pruritis and related skin conditions
WO2009018326A3 (en) Soluble pyrone analogs methods and compositions
WO2008014200A3 (en) Cyclosporin compositions
WO2010034015A3 (en) Modulating the alternative complement pathway
GB2464645A (en) Phosphorylated pyrone analogs and methods
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
SI2328417T1 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF beta-AMYLOID DISEASES AND SYNUCLEINOPATHIES
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
WO2009099467A3 (en) Cyclosporin compositions
ZA201203281B (en) Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals
WO2009041663A1 (en) Agent for prevention and/or treatment of skin diseases
WO2010074936A3 (en) Enzastaurin for the treatment of cancer
AU2009231892A8 (en) Methods of diagnosing, preventing and treating bone mass diseases
WO2012037008A3 (en) Therapy for mll-rearranged leukemia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09770545

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09770545

Country of ref document: EP

Kind code of ref document: A2